Avalo Therapeutics announced positive Phase 2 results for Abdakibart (AVTX-009) in treating moderate to severe hidradenitis suppurativa (HS). The LOTUS trial met its primary endpoint with response rates over 42% at Week 16, the highest observed in trials of this size, showing significant improvement in key clinical measures. Abdakibart was well tolerated with a favorable safety profile, and Avalo plans to advance the drug into Phase 3 registrational trials. This progress highlights the potential of IL-1β inhibition as a new treatment option for HS patients.
A new study found that adults with alcohol use disorder (AUD) who started treatment with GLP-1 receptor agonists like semaglutide and tirzepatide had significantly fewer alcohol-related hospitalizations compared to those on other diabetes or obesity ...
D.R. Horton reported Q3 earnings per share of $3.20, beating estimates, and revenues of $9.23 billion, slightly above expectations. Goldman Sachs raised its price target to $190 and maintained a "Buy" rating, signaling strong growth potential. Despit...
Interactive Brokers reported a strong Q2 with diluted EPS of $0.69 and net revenues of $1.90 billion, both exceeding analyst expectations. The company saw a 34% increase in client accounts and a 40% rise in client equity, driven by higher trading act...
United Rentals is set to report its Q2 2026 earnings on July 22, with analysts forecasting an 11.5% rise in earnings per share to $11.67 and a 7.3% increase in revenue to $4.23 billion. The growth is driven by strong rental demand and efficient equip...
Capital One has completed moving its debit cards to the Discover network and is now testing the migration of its credit cards to the same network. The company reported a 26% year-over-year increase in credit card purchase volume, reaching $253.8 bill...
